Overview, prevention and management of chemotherapy extravasation  

作　　者：Firas Y Kreidieh Hiba A Moukadem Nagi S El Saghir 

机构地区：[1]Division of Hematology-Oncology, Department of Internal Medicine, American University of Beirut Medical Center [2]Breast Center of Excellence, NK Basile Cancer Institute, American University of Beirut Medical Center

出　　处：《World Journal of Clinical Oncology》2016年第1期87-97,共11页世界临床肿瘤学杂志（英文版）

摘　　要：Chemotherapy extravasation remains an accidental complication of chemotherapy administration and may result in serious damage to patients. We review in this article the clinical aspects of chemotherapy extravasation and latest advances in definitions, classification, pre-vention, management and guidelines. We review the grading of extravasation and tissue damage according to various chemotherapeutic drugs and present an update on treatment and new antidotes including dexrazoxane for anthracyclines extravasation. We highlight the importance of education and training of the oncology team for prevention and prompt pharmacological and non-pharmacological management and stress the availability of new antidotes like dexrazoxane wherever anthracyclines are being infused.Chemotherapy extravasation remains an accidental complication of chemotherapy administration and may result in serious damage to patients. We review in this article the clinical aspects of chemotherapy extravasation and latest advances in definitions, classification, pre-vention, management and guidelines. We review the grading of extravasation and tissue damage according to various chemotherapeutic drugs and present an update on treatment and new antidotes including dexrazoxane for anthracyclines extravasation. We highlight the importance of education and training of the oncology team for prevention and prompt pharmacological and non-pharmacological management and stress the availability of new antidotes like dexrazoxane wherever anthracyclines are being infused.

关 键 词：CHEMOTHERAPY EXTRAVASATION Vesicant Tissue damage Dimethyl SULFOXIDE DEXRAZOXANE ANTIDOTE HYALURONIDASE 

分 类 号：R730.53[医药卫生—肿瘤]